Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment

27 Nov 2021

Abstract excerpt

Osimertinib has been an effective second-line treatment in EGFR mutant NSCLC patients; however, resistance inevitably occurs. DNA methylation has been previously implicated in NSCLC progression and often in therapy resistance, however its distinct role in osimertinib resistance is not elucidated as yet. In the present study, we directly compared DNA methylation of nine selected genes (RASSF1A, RASSF10, APC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34885084
DOI: 10.3390/cancers13235974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib TreatmentPMID 34885084Read ↗

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detectionSemantic proximity Read ↗

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatmentSemantic proximity Read ↗

Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patientsSemantic proximity Read ↗

DNA methylation analysis in plasma for early diagnosis in lung adenocarcinomaSemantic proximity Read ↗

Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancerSemantic proximity Read ↗

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib responseSemantic proximity Read ↗

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.Semantic proximity Read ↗

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionSemantic proximity Read ↗

DNA Methylation Analysis of the SHOX2 and RASSF1A Panel Using Cell-Free DNA in the Diagnosis of Malignant Pleural EffusionSemantic proximity Read ↗

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.Semantic proximity Read ↗

Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasmaSemantic proximity Read ↗

Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer RiskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.